Clinical Trials Logo

Batten Disease clinical trials

View clinical trials related to Batten Disease.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT05174039 Active, not recruiting - Batten Disease Clinical Trials

An Open-label Safety, Pharmacokinetic, and Efficacy Study of Miglustat for the Treatment of CLN3 Disease

Start date: February 2, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This is an open label study in approximately 6 subjects in 2 centers to assess the safety, PK, and efficacy of the maximum tolerable dose (MTD) of oral miglustat (100 mg once daily [QD] to 200 mg 3 times daily [TID]) in subjects ≥ 17 years of age with CLN3 disease over a period of 104 weeks.

NCT ID: NCT04273243 Active, not recruiting - Batten Disease Clinical Trials

Long-Term Follow Up of CLN6 Batten Disease Subjects Following Gene Transfer

Start date: January 24, 2020
Phase:
Study type: Observational

This is a long-term safety and efficacy study in subjects with CLN6 Batten disease who previously received a single intrathecal administration of AT-GTX-501.

NCT ID: NCT03770572 Active, not recruiting - Batten Disease Clinical Trials

Gene Therapy for Children With CLN3 Batten Disease

Start date: November 13, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

This is a phase 1/2, open-label, single dose, dose-escalation clinical trial to evaluate the safety and efficacy of AT-GTX-502 (previous NCH Code: scAAV9.P546.CLN3) delivered intrathecally into the lumbar spinal cord region of subjects with CLN3 Batten disease.